| Literature DB >> 31684122 |
Mary R Yan1,2, Robert Welch3, Elaine C Rush4, Xuesong Xiang5, Xin Wang6.
Abstract
A sustainable food supply is an ever-growing public and planetary health concern influenced by food culture, food practices, and dietary patterns. Globally, the consumption of plant foods that offer physiological and biochemical benefits is increasing. In recent years, products made from yacon (Smallanthus sonchifolius) tubers and leaves, e.g., in the form of syrup, powder, and herbal tea, have steadily emerged with scientific evidence to validate their possible health claims. Yacon was introduced to New Zealand in 1966, and its products can now be produced on a commercial scale. This paper reviews literature published mainly in the last 10 years concerning the health-related properties of yacon as a wholesome foodstuff and its bioactive components, e.g., fructooligosaccharides. Literature was sourced from Web of Science, PubMed, EBSCO Health, and Google Scholar up to June 2019. The potential markets for yacon in the field of food technology and new dietotherapy applications are discussed. Furthermore, the unique features of New Zealand-produced yacon syrup are introduced as a case study. The paper explores the scientific foundation in response to the growing public interest in why and how to use yacon.Entities:
Keywords: chronic diseases; fructooligosaccharides; inulin; phenolic compounds; prebiotic; public health; yacon
Mesh:
Substances:
Year: 2019 PMID: 31684122 PMCID: PMC6893727 DOI: 10.3390/nu11112632
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Yacon plants grown in New Zealand, annotated with nutritional and chemical composition of yacon leaf and tuber (photos: Crop and Food Research New Zealand).
Figure 2Fructooligosaccharides (FOS) work in the gastrointestinal tract as prebiotics; SCFAs: short chain fatty acids.
Summary of studies on yacon (Smallanthus sonchifolius) in vitro and in vivo in human or animal models.
| Author(s) | Year | Stated Yacon Source | Component(s) Under Study | Study Design | Physiological Effect(s) | |
|---|---|---|---|---|---|---|
| Method | In Vivo | |||||
| Cocato et al. [ | 2019 | Yacon root flour | FOS* | Rats (Wistar) | Improved mineral absorption | |
| Machado et al. [ | 2019 | Yacon root flour | FOS | Human (BMI 30 ± 2.4 kg m-2) | Improved body composition | |
| dos Santos et al. [ | 2018 | Yacon leaf extract | Rats (Wistar) | Significant reduction in glycemia | ||
| Gomes da Silva et al. [ | 2017 | Yacon syrup | Human | Improved satiety effects | ||
| dos Santos et al. [ | 2017 | Yacon leaf extract | Rats (Wistar, diabetic) | Improved glycemic control | ||
| An et al. [ | 2016 | Yacon root extract | Inulin | Mice (Kuming); | Antidepressant-like effects | |
| Baroni et al. [ | 2016 | Yacon leaf extract | Phenolics | Rats (Wistar, diabetic) | Improved insulin sensitivity | |
| da Silva et al. [ | 2015 | Yacon root extract | FOS | Rats (Wistar) | Anti-cancer (against colon carcinogenesis on the early phases) | |
| de Ford et al. [ | 2015 | Yacon leaf extract | In vitro | Anti-cancer | ||
| Habib et al. [ | 2015 | Yacon root flour | Rats (Wistar, diabetic) | Antidiabetic effects | ||
| Jimenez et al. [ | 2015 | Yacon root | FOS | Rats (Wistar) | Improved intestinal microflora | |
| Lee et al. [ | 2015 | Yacon extract | In vitro | Anti-cancer (inhibited cell proliferation) | ||
| Russo et al. [ | 2015 | Yacon leaf extract | Phenolics | In vitro | Antioxidant effects | |
| Sousa et al. [ | 2015 | Yacon tuber flour | Phenolics | In vitro | Antioxidant effects | |
| Sugahara et al. [ | 2015 | Yacon leaf extract | Phenolics | In vitro | Antioxidant effects | |
| Scheid et al. [ | 2014 | Yacon root powder | FOS | Human (>60 years old) | Diabetes management, no side effects observed | |
| Vaz-Tostes et al. [ | 2014 | Yacon root flour | FOS | Human (ages 2–5 years old) | Improved systemic immunity | |
| Oliverra et al. [ | 2013 | Yacon leaf extract | In vitro | Anti-inflammatory | ||
| Oliverra et al. [ | 2013 | Yacon root extract | Fructan | Rats (induced type 1 diabetic) | Antidiabetic effects | |
| Satoh et al. [ | 2013 | Yacon tuber extract | Rats (Zucker fa/fa) | Improved insulin sensitivity | ||
| Utami et al. [ | 2013 | Yacon tuber powder | FOS | Rats (Sprague Dawley) | Improved intestinal microflora | |
| Velez et al. [ | 2013 | Yacon root flour | FOS | Mice (BALB/c) | Regulated intestinal microflora | |
| Campos et al. [ | 2012 | Yacon root flour | FOS | Guinea pig | Improved intestinal microflora | |
| Delgado et al. [ | 2012 | Yacon root flour | FOS | Mice (BALB/c) | Improved immunity efficiency | |
| de Moura et al. [ | 2012 | Yacon root extract | FOS | Rats (Wistar) | Anti-cancer (against colon carcinogenesis on the early phases) | |
| Roselino et al. [ | 2012 | Yacon root extract | Fructan | Rats (Wistar) | Improved lipid profiles | |
| Habib et al. [ | 2011 | Yacon root flour | FOS | Rats (Wistar) | Antidiabetic and hypolipidemic effects | |
| Lobo et al. [ | 2011 | Yacon root flour | Inulin | Rats (Wistar) | Improved mineral absorption | |
| Siriwan et al. [ | 2011 | Yacon leaf extract | In vitro | Anti-cancer (inhibited cancer cell proliferation) | ||
| Siriwan et al. [ | 2011 | Yacon leaf extract | In vitro | Anti-cancer (inhibited cancer cell proliferation) | ||
| Bonet et al. [ | 2010 | Yacon root flour | Mice (BALB/c) | Improved intestinal microflora (growth of | ||
| Genta et al. [ | 2010 | Yacon leaf extract | Phenolics | Rats (Wistar) | Hypoglycemic effects | |
| Joung et al. [ | 2010 | Yacon leaf extract | In vitro | Antimicrobial effects | ||
| Raga et al. [ | 2010 | Yacon leaf extract | Phenolics | Mice (albino) | Hypoglycemic effects | |
| Yun et al. [ | 2010 | Yacon root ingestion | Human (a 55-years-old woman) | Anaphylaxis1 | ||
| Genta et al. [ | 2009 | Yacon syrup | Human (obese with mild dyslipidemia) | Improve insulin-resistance, and satiety effects | ||
| Park et al. [ | 2009 | Yacon tuber extract | Rats (Sprague Dawley, diabetic) | Improved glycemic control | ||
| Baroni et al. [ | 2008 | Yacon leaf extract | Phenolics | Rats (Wistar) | Hypoglycemic effects | |
| Geyer et al. [ | 2008 | Yacon syrup | FOS | Human | Improved the colonic transit | |
| Lobo et al. [ | 2007 | Yacon root flour | Rats (Wistar) | Improved mineral absorption | ||
| Genta et al. [ | 2005 | Yacon root flour | FOS | Rats (Wistar) | No adverse side effects observed2 | |
| Valentova et al. [ | 2004 | Yacon leaf extract | Rats (diabetic) | Anti-hyperglycemic effects | ||
* FOS: fructooligosaccharides. 1 A reported case of adverse side effects. 2 Toxicity study.
Figure 3Yacon plants were brought to New Zealand by Crop and Food Crown Research, and trials were carried out in small plots in different regions on the basic agronomy of the crop to optimize growing and harvesting conditions.